Board of Directors
Edward Mathers, Chairman
New Enterprise Associates
Edward Mathers has served on the Ra Pharma® Board of Directors since 2010. Since August 2008, Mr. Mathers has been a Partner at New Enterprise Associates, Inc., or NEA, a private venture capital firm focusing on technology and healthcare investments. Mr. Mathers is a director of Liquidia Technologies, Inc., Rhythm Pharmaceuticals, Inc., Envisia Therapeutics, Inc., Synlogic, Inc., Mirna Therapeutics, Inc., Lumos Pharma, Inc., Ziarco, Inc., Amplyx Pharmaceuticals, Inc. and ObsEva SA. He is also a member of NC State’s College of Sciences Foundation board. Mr. Mathers earned his B.S. in Chemistry from North Carolina State University.
Peter Tuxen Bisgaard
Peter Tuxen Bisgaard has served as a member of the Ra Pharma Board of Directors since 2015. Since 2009, Mr. Bisgaard has been employed as a Partner at Novo Ventures (US) Inc., which provides consultancy services to Novo A/S, a Danish limited liability company that manages investments and financial assets. He is a member of the Board of Directors of Ceterix Orthopaedics, Entasis Therapeutics and Outpost Medicine, as well as Chairman of the Board of Directors of HTG Molecular Diagnostics, Inc. Mr. Bisgaard obtained an M.Sc. in 1998 from the Technical University of Denmark and was at the same time awarded a post graduate degree in Mathematical Modeling in Economics by the European Consortium for Mathematics in the Industry.
Robert Heft, Ph.D.
Robert Heft, Ph.D., has served on the Ra Pharma Board of Directors since March 2016. Dr. Heft currently serves as Chief Executive Officer of Zingenix Ltd., a company focused on gene therapy for severe orphan disorders. Prior to Zingenix, Dr. Heft was President, Chief Executive Officer, and member of the Board of Directors of Enobia Pharma Inc. from 2005 to 2012. Dr. Heft currently serves on the boards of Zingenix Ltd., VisionGate, Inc., Lumos Pharma, Inc., and Clementia Pharmaceuticals, Inc., and as Chairman of the Board of Eloxx Pharmaceuticals, Ltd. He also serves on the Advisory Board of Sectoral Asset Management. Dr. Heft received a Bachelor of Engineering Degree from Cornell University, a Master of Engineering Degree from McGill University and a Ph.D. from the Massachusetts Institute of Technology in Genetic Engineering and Radiological Sciences.
Jason Lettmann has served as a member of Ra Pharma’s Board of Directors since 2015. Mr. Lettmann has been a Partner of Morgenthaler Ventures since June 2009 and a Partner of Lightstone Ventures since March 2012. Mr. Lettmann currently represents Morgenthaler and Lightstone on the boards of a number of their portfolio companies including Alexo Therapeutics Ltd., Carrick Therapeutics Ltd., FIRE1 Ltd., Promedior Inc., Relievant Medsystems Inc., Second Genome Inc., and Vapotherm Inc. Prior to joining Morgenthaler in 2009, Mr. Lettmann was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. Mr. Lettmann has an M.B.A. from the University of Michigan’s Ross School of Business and a B.A. from the University of Iowa.
Timothy Pearson has served as a member of Ra Pharma’s Board of Directors since May 2016. Mr. Pearson currently serves as Chief Financial Officer of TESARO, Inc., an oncology-focused biopharmaceutical company, where he has served since May 2014. Prior to joining TESARO, from August 2011 to July 2012, Mr. Pearson served as an Executive Vice President and the Chief Financial Officer of Catalyst Health Solutions, Inc. where he led the finance and strategic planning functions. Mr. Pearson holds a B.S. in Business Administration from the University of Delaware, an M.S. in Finance from Loyola College and a B.S. in Accounting from the University of Maryland University College. He is also a Certified Public Accountant.
RA Capital Management
Rajeev Shah has served as a member of the board of directors of Ra Pharma since July 2015. Mr. Shah is a Partner and Portfolio Manager at RA Capital Management, LLC, an investment advisory firm that has been investing in health care companies since 2002. Mr. Shah received a B.A. in Chemistry from Cornell University.
Douglas Treco, Ph.D.
Doug Treco has been Chief Executive Officer of Ra Pharma since he co-founded the Company in June 2008, and serves on the Company’s Board of Directors. Dr. Treco was an Entrepreneur-in-Residence at Morgenthaler Ventures from January 2008 to May 2014. In 1988, he co-founded Transkaryotic Therapies Inc., or TKT, a multi-platform biopharmaceutical company developing protein and gene therapy products, which was acquired by Shire Pharmaceuticals Group plc. Dr. Treco was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School from 2004 to 2007. Dr. Treco received his Ph.D. in Biochemistry and Molecular Biology from the State University of New York, Stony Brook, and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital.